versandkostenfreie Lieferung
i.d.R. sofortige Verfügbarkeit
aller Studien u. Marktanalysen
Bezahlung auf Rechnung
oder per Kreditkarte
Gerne helfen wir Ihnen kostenfrei bei der Recherche nach Studien und Marktanalysen:
Tel.: +49 (0)221 788 748-11
Fax.: +49 (0)221 788 748-48
E-Mail: service[at]marktforschung.de
Studie Frauenkrankheiten (Gynäkologie)
Mit der Wahl einer Publikation aus unserem Studien Shops zum Thema „Studie Frauenkrankheiten (Gynäkologie)“ erhalten Sie topaktuelle Unterlagen zur Marktsituation. Sämtliche Marktanalysen stammen von unseren renommierten Partnern aus der Marktforschung und enthalten umfassende Marktdaten und -prognosen. Wählen Sie einen der nachfolgenden Einträge aus, um genauere Informationen zu der von Ihnen gewählten Marktanalyse Frauenkrankheiten (Gynäkologie) einzusehen.
Mit Hilfe der Suchfunktion in der linken Seitenleiste erhalten Sie eine treffsichere Auswahl aktueller nationaler und internationaler Publikationen aus dem Themenbereich „Marktanalyse Frauenkrankheiten (Gynäkologie)“. Gerne bieten wir Ihnen auch eine persönliche und fachlich fundierte Beratung bei der Auswahl einer passenden Frauenkrankheiten (Gynäkologie) Studie. Dazu nutzen Sie bitte unser Kontaktformular oder rufen in unserem Kölner Büro an.
Studien / Marktanalysen aus der Kategorie Frauenkrankheiten (Gynäkologie)
| Titel | ||
|---|---|---|
Acute Inflammation – Pipeline Review, H1 2013Von: Global Markets Direct
|
5 / 2013 | 1.546,79 € |
|
Acute Inflammation — Pipeline Review, H1 2013 |
||
Ovarian Disease – Pipeline Review, H1 2013Von: Global Markets Direct
|
5 / 2013 | 1.546,79 € |
|
Ovarian Disease — Pipeline Review, H1 2013 |
||
Premenstrual Syndrome – Pipeline Review, H1 2013Von: Global Markets Direct
|
5 / 2013 | 1.546,79 € |
|
Premenstrual Syndrome — Pipeline Review, H1 2013 |
||
Female Hypoactive Sexual Desire Disorder – Pipeline Review, H1 2013Von: Global Markets Direct
|
4 / 2013 | 1.546,79 € |
|
Female Hypoactive Sexual Desire Disorder — Pipeline Review, H1 2013 |
||
Cervical Dysplasia – Pipeline Review, H1 2013Von: Global Markets Direct
|
3 / 2013 | 1.546,79 € |
|
Cervical Dysplasia — Pipeline Review, H1 2013 |
||
| 3 / 2013 | 6.179,43 € | |
|
EpiCast Report: Postmenopausal Vaginal Atrophy - Epidemiology Forecast to 2022 |
||
Female Sexual Dysfunction – Pipeline Review, H1 2013Von: Global Markets Direct
|
3 / 2013 | 1.546,79 € |
|
Female Sexual Dysfunction — Pipeline Review, H1 2013 |
||
Menopausal Disorders – Pipeline Review, H1 2013Von: Global Markets Direct
|
3 / 2013 | 1.546,79 € |
|
Menopausal Disorders — Pipeline Review, H1 2013 |
||
Menopausal Hot Flashes – Pipeline Review, H1 2013Von: Global Markets Direct
|
3 / 2013 | 1.546,79 € |
|
Menopausal Hot Flashes — Pipeline Review, H1 2013 |
||
Uterine Fibroids – Pipeline Review, H1 2013Von: Global Markets Direct
|
3 / 2013 | 1.546,79 € |
|
Uterine Fibroids — Pipeline Review, H1 2013 |
||
Vaginal Atrophy (Atrophic Vaginitis) – Pipeline Review, H1 2013Von: Global Markets Direct
|
3 / 2013 | 1.546,79 € |
|
Vaginal Atrophy (Atrophic Vaginitis) — Pipeline Review, H1 2013 |
||
Contraceptives – Pipeline Review, H1 2013Von: Global Markets Direct
|
2 / 2013 | 1.546,79 € |
|
Contraceptives — Pipeline Review, H1 2013 |
||
Dysmenorrhea – Pipeline Review, H1 2013Von: Global Markets Direct
|
2 / 2013 | 1.546,79 € |
|
Dysmenorrhea — Pipeline Review, H1 2013 |
||
Endometriosis – Pipeline Review, H1 2013Von: Global Markets Direct
|
2 / 2013 | 1.546,79 € |
|
Endometriosis — Pipeline Review, H1 2013 |
||
Women Infertility – Pipeline Review, H1 2013Von: Global Markets Direct
|
2 / 2013 | 1.546,79 € |
|
Women Infertility — Pipeline Review, H1 2013 |
||
Premature Labor (Tocolysis) – Pipeline Review, H2 2012Von: Global Markets Direct
|
12 / 2012 | 1.546,79 € |
|
Premature Labor (Tocolysis) — Pipeline Review, H2 2012 |
||
Vasomotor Symptoms of Menopause – Pipeline Review, H2 2012Von: Global Markets Direct
|
12 / 2012 | 1.546,79 € |
|
Vasomotor Symptoms of Menopause — Pipeline Review, H2 2012 |
||
| 11 / 2012 | 2.706,88 € | |
|
Contraceptives Market to 2018 - Safety Concerns Plague Drospirenone-containing Birth Control Pills and Long-term Use of Estrogen |
||
Premature Ovarian Failure – Pipeline Review, H2 2012Von: Global Markets Direct
|
11 / 2012 | 1.546,79 € |
|
Premature Ovarian Failure — Pipeline Review, H2 2012 |
||
Premenstrual Syndrome – Pipeline Review, H2 2012Von: Global Markets Direct
|
11 / 2012 | 1.546,79 € |
|
Premenstrual Syndrome — Pipeline Review, H2 2012 |
||
| 11 / 2012 | 2.706,88 € | |
|
Women’s Health Therapeutics Market to 2018 - Unmet Need for Safe and Effective Treatments due to Unfavorable Risk/Benefit Profile Associated with Hormone Replacement Therapy |
||
Endometriosis Global Clinical Trials Review, H2, 2012Von: GlobalData
|
10 / 2012 | 1.933,49 € |
|
Endometriosis Global Clinical Trials Review, H2, 2012 |
||
Primary Dysmenorrhea – Pipeline Review, H2 2012Von: Global Markets Direct
|
10 / 2012 | 1.546,79 € |
|
Primary Dysmenorrhea — Pipeline Review, H2 2012 |
||
Cervical Dysplasia – Pipeline Review, H2 2012Von: Global Markets Direct
|
9 / 2012 | 1.546,79 € |
|
Cervical Dysplasia — Pipeline Review, H2 2012 |
||
Female Sexual Dysfunction – Pipeline Review, H2 2012Von: Global Markets Direct
|
9 / 2012 | 1.546,79 € |
|
Female Sexual Dysfunction — Pipeline Review, H2 2012 |
||
Menopausal Disorders – Pipeline Review, H2 2012Von: Global Markets Direct
|
9 / 2012 | 1.546,79 € |
|
Menopausal Disorders — Pipeline Review, H2 2012 |
||
Menopausal Disorders – Pipeline Review, H2 2012Von: Global Markets Direct
|
9 / 2012 | 1.546,79 € |
|
Menopausal Disorders — Pipeline Review, H2 2012 |
||
Menopausal Hot Flashes – Pipeline Review, H2 2012Von: Global Markets Direct
|
9 / 2012 | 1.546,79 € |
|
Menopausal Hot Flashes — Pipeline Review, H2 2012 |
||
Other Gynecological Disorders – Pipeline Review, H2 2012Von: Global Markets Direct
|
9 / 2012 | 1.546,79 € |
|
Other Gynecological Disorders — Pipeline Review, H2 2012 |
||
Pregnancy – Pipeline Review, H2 2012Von: Global Markets Direct
|
9 / 2012 | 1.546,79 € |
|
Pregnancy — Pipeline Review, H2 2012 |
||
Uterine Fibroids – Pipeline Review, H2 2012Von: Global Markets Direct
|
9 / 2012 | 1.546,79 € |
|
Uterine Fibroids — Pipeline Review, H2 2012 |
||
Vaginal Atrophy (Atrophic Vaginitis) – Pipeline Review, H2 2012Von: Global Markets Direct
|
9 / 2012 | 1.546,79 € |
|
Vaginal Atrophy (Atrophic Vaginitis) — Pipeline Review, H2 2012 |
||
Abortion – Pipeline Review, H2 2012Von: Global Markets Direct
|
8 / 2012 | 1.546,79 € |
|
Abortion — Pipeline Review, H2 2012 |
||
Contraceptives – Pipeline Review, H2 2012Von: Global Markets Direct
|
8 / 2012 | 1.546,79 € |
|
Contraceptives — Pipeline Review, H2 2012 |
||
Dysmenorrhea – Pipeline Review, H2 2012Von: Global Markets Direct
|
8 / 2012 | 1.546,79 € |
|
Dysmenorrhea — Pipeline Review, H2 2012 |
||
Endometriosis – Pipeline Review, H2 2012Von: Global Markets Direct
|
8 / 2012 | 1.546,79 € |
|
Endometriosis — Pipeline Review, H2 2012 |
||
Female Infertility – Pipeline Review, H2 2012Von: Global Markets Direct
|
8 / 2012 | 1.546,79 € |
|
Female Infertility — Pipeline Review, H2 2012 |
||
Labor And Delivery – Pipeline Review, H2 2012Von: Global Markets Direct
|
8 / 2012 | 1.546,79 € |
|
Labor And Delivery — Pipeline Review, H2 2012 |
||
Ovarian Disease – Pipeline Review, H2 2012Von: Global Markets Direct
|
8 / 2012 | 1.546,79 € |
|
Ovarian Disease — Pipeline Review, H2 2012 |
||
Polycystic Ovarian Syndrome – Pipeline Review, H2 2012Von: Global Markets Direct
|
8 / 2012 | 1.546,79 € |
|
Polycystic Ovarian Syndrome — Pipeline Review, H2 2012 |
||
Premenstrual Dysphoric Disorder (PMDD) – Pipeline Review, H2 2012Von: Global Markets Direct
|
8 / 2012 | 1.546,79 € |
|
Premenstrual Dysphoric Disorder (PMDD) — Pipeline Review, H2 2012 |
||
Cervical Dysplasia Global Clinical Trials Review, H2, 2012Von: GlobalData
|
7 / 2012 | 1.933,49 € |
|
Cervical Dysplasia Global Clinical Trials Review, H2, 2012 |
||
Uterine Fibroids Global Clinical Trials Review, H2, 2012Von: GlobalData
|
7 / 2012 | 1.933,49 € |
|
Uterine Fibroids Global Clinical Trials Review, H2, 2012 |
||
Pregnancy Global Clinical Trials Review, H1, 2012Von: GlobalData
|
6 / 2012 | 1.933,49 € |
|
Pregnancy Global Clinical Trials Review, H1, 2012 |
||
Premature Labor (Tocolysis) – Pipeline Review, H1 2012Von: Global Markets Direct
|
6 / 2012 | 386,70 € |
|
Premature Labor (Tocolysis) — Pipeline Review, H1 2012 |
||
Premenstrual Syndrome – Pipeline Review, H1 2012Von: Global Markets Direct
|
5 / 2012 | 386,70 € |
|
Premenstrual Syndrome — Pipeline Review, H1 2012 |
||
Post Menopausal Osteoporosis – Pipeline Review, H1 2012Von: Global Markets Direct
|
4 / 2012 | 386,70 € |
|
Post Menopausal Osteoporosis — Pipeline Review, H1 2012 |
||
Primary Dysmenorrhea – Pipeline Review, H1 2012Von: Global Markets Direct
|
4 / 2012 | 386,70 € |
|
Primary Dysmenorrhea — Pipeline Review, H1 2012 |
||
Cervical Dysplasia – Pipeline Review, H1 2012Von: Global Markets Direct
|
3 / 2012 | 386,70 € |
|
Cervical Dysplasia — Pipeline Review, H1 2012 |
||
Female Sexual Dysfunction – Pipeline Review, H1 2012Von: Global Markets Direct
|
3 / 2012 | 386,70 € |
|
Female Sexual Dysfunction — Pipeline Review, H1 2012 |
||
Menopausal Disorders – Pipeline Review, H1 2012Von: Global Markets Direct
|
3 / 2012 | 386,70 € |
|
Menopausal Disorders — Pipeline Review, H1 2012 |
||
Menopausal Hot Flashes – Pipeline Review, H1 2012Von: Global Markets Direct
|
3 / 2012 | 386,70 € |
|
Menopausal Hot Flashes — Pipeline Review, H1 2012 |
||
Uterine Leiomyoma (Uterine Fibroids) – Pipeline Review, H1 2012Von: Global Markets Direct
|
3 / 2012 | 386,70 € |
|
Uterine Leiomyoma (Uterine Fibroids) — Pipeline Review, H1 2012 |
||
Vaginal Atrophy – Pipeline Review, H1 2012Von: Global Markets Direct
|
3 / 2012 | 386,70 € |
|
Vaginal Atrophy — Pipeline Review, H1 2012 |
||
Dysmenorrhea – Pipeline Review, H1 2012Von: Global Markets Direct
|
2 / 2012 | 386,70 € |
|
Dysmenorrhea — Pipeline Review, H1 2012 |
||
Endometriosis – Pipeline Review, H1 2012Von: Global Markets Direct
|
2 / 2012 | 386,70 € |
|
Endometriosis — Pipeline Review, H1 2012 |
||
Female Infertility – Pipeline Review, H1 2012Von: Global Markets Direct
|
2 / 2012 | 386,70 € |
|
Female Infertility — Pipeline Review, H1 2012 |
||
Polycystic Ovarian Syndrome – Pipeline Review, H1 2012Von: Global Markets Direct
|
2 / 2012 | 386,70 € |
|
Polycystic Ovarian Syndrome — Pipeline Review, H1 2012 |
||
| 2 / 2012 | 773,40 € | |
|
Post Menopausal Osteoporosis Global Clinical Trials Review, H1, 2012 |
||
| 2 / 2012 | 3.089,71 € | |
|
Postmenopausal Vaginal Atrophy Therapeutics - Pipeline Assessment and Market Forecasts to 2019 |
||
Digital Mammography Market in the US 2010–2014Von: Technavio
|
1 / 2012 | 1.160,09 € |
|
TechNavio’s analysts forecast the Digital Mammography market in the US to grow at a CAGR of 6.4 percent over the period 2010—2014. One of the key factors contributing to this market growth is the recent advancement in 3D Tomosynthesis. The Digital Mammography market in the US has also been witnessing adoption to dual-energy digital mammography. However, growth of magnetic resonance imaging (MRI) could pose a challenge to the gro... |
||
| 1 / 2012 | 2.706,88 € | |
|
Women’s Health Therapeutics Market to 2017 - High Unmet Need will Drive Uptake of Novel Drugs Such as Prolia and Odanocantib in the Menopause and Osteoporosis Market |
||
| 12 / 2011 | 2.706,88 € | |
|
Fibromyalgia Therapeutics - Pipeline Assessment and Market Forecasts to 2018 |
||
Cervical Dysplasia Global Clinical Trials Review, H2, 2011Von: GlobalData
|
11 / 2011 | 773,40 € |
|
Cervical Dysplasia Global Clinical Trials Review, H2, 2011 |
||
| 11 / 2011 | 2.706,88 € | |
|
Fibromyalgia Therapeutics - Pipeline Assessment and Market Forecasts to 2018 |
||
Ovarian Disease Global Clinical Trials Review, H2, 2011Von: GlobalData
|
11 / 2011 | 773,40 € |
|
Ovarian Disease Global Clinical Trials Review, H2, 2011 |
||
| 11 / 2011 | 2.706,88 € | |
|
Polycystic Ovarian Syndrome (PCOS) Therapeutics - Pipeline Assessment and Market Forecasts to 2018 |
||
| 11 / 2011 | 2.706,88 € | |
|
Polycystic Ovarian Syndrome (PCOS) Therapeutics - Pipeline Assessment and Market Forecasts to 2018 |
||
Premenstrual Syndrome - Pipeline Review, H2 2011Von: Global Markets Direct
|
11 / 2011 | 386,70 € |
|
Premenstrual Syndrome - Pipeline Review, H2 2011 |
||
Cervical Dysplasia - Pipeline Review, H2 2011Von: Global Markets Direct
|
10 / 2011 | 386,70 € |
|
Cervical Dysplasia - Pipeline Review, H2 2011 |
||
| 10 / 2011 | 2.706,88 € | |
|
Contraceptives Market to 2017 - Hormonal Contraceptives and Strong Pipeline to Drive the Growth in Future |
||
Female Sexual Dysfunction - Pipeline Review, H2 2011Von: Global Markets Direct
|
10 / 2011 | 386,70 € |
|
Female Sexual Dysfunction - Pipeline Review, H2 2011 |
||
Menopausal Disorders - Pipeline Review, H2 2011Von: Global Markets Direct
|
10 / 2011 | 386,70 € |
|
Menopausal Disorders - Pipeline Review, H2 2011 |
||
Menopausal Hot Flashes - Pipeline Review, H2 2011Von: Global Markets Direct
|
10 / 2011 | 386,70 € |
|
Menopausal Hot Flashes - Pipeline Review, H2 2011 |
||
| 10 / 2011 | 773,40 € | |
|
Polycystic Ovarian Syndrome Global Clinical Trials Review, H2 2011 |
||
Uterine Fibroids - Pipeline Review, H2 2011Von: Global Markets Direct
|
10 / 2011 | 386,70 € |
|
Uterine Fibroids - Pipeline Review, H2 2011 |
||
Uterine Fibroids Global Clinical Trials Review, H2 2011Von: GlobalData
|
10 / 2011 | 773,40 € |
|
Uterine Fibroids Global Clinical Trials Review, H2 2011 |
||
Vaginal Atrophy - Pipeline Review, H2 2011Von: Global Markets Direct
|
10 / 2011 | 386,70 € |
|
Vaginal Atrophy - Pipeline Review, H2 2011 |
||
Dysmenorrhea - Pipeline Review, H2 2011Von: Global Markets Direct
|
9 / 2011 | 386,70 € |
|
Dysmenorrhea - Pipeline Review, H2 2011 |
||
Endometriosis - Pipeline Review, H2 2011Von: Global Markets Direct
|
9 / 2011 | 386,70 € |
|
Endometriosis - Pipeline Review, H2 2011 |
||
Infertility - Pipeline Review, H2 2011Von: Global Markets Direct
|
9 / 2011 | 386,70 € |
|
Infertility - Pipeline Review, H2 2011 |
||
Menopausal Disorders Global Clinical Trials Review, H2, 2011Von: GlobalData
|
9 / 2011 | 773,40 € |
|
Menopausal Disorders Global Clinical Trials Review, H2, 2011 |
||
Polycystic Ovarian Syndrome - Pipeline Review, H2 2011Von: Global Markets Direct
|
9 / 2011 | 386,70 € |
|
Polycystic Ovarian Syndrome - Pipeline Review, H2 2011 |
||
| 9 / 2011 | 2.706,88 € | |
|
Women’s Infertility Therapeutics - Pipeline Assessment and Market Forecasts to 2018 |
||
| 8 / 2011 | 1.546,79 € | |
|
Acromegaly and Gigantism Therapeutics - Pipeline Assessment and Market Forecasts to 2017 |
||
Endometriosis Global Clinical Trials Review, H2, 2011Von: GlobalData
|
8 / 2011 | 773,40 € |
|
Endometriosis Global Clinical Trials Review, H2, 2011 |
||
Post Menopausal Osteoporosis - Pipeline Review, H2 2011Von: Global Markets Direct
|
8 / 2011 | 386,70 € |
|
Post Menopausal Osteoporosis - Pipeline Review, H2 2011 |
||
| 8 / 2011 | 1.546,79 € | |
|
Postmenopausal Osteoporosis Therapeutics - Pipeline Assessment and Market Forecasts to 2017 |
||
Primary Dysmenorrhea - Pipeline Review, H2 2011Von: Global Markets Direct
|
8 / 2011 | 386,70 € |
|
Primary Dysmenorrhea - Pipeline Review, H2 2011 |
||
Endometriosis Global Clinical Trials Review, Q2, 2011Von: GlobalData
|
6 / 2011 | 773,40 € |
|
Endometriosis Global Clinical Trials Review, Q2, 2011 |
||
Infertility Global Clinical Trials Review, Q2, 2011Von: GlobalData
|
6 / 2011 | 773,40 € |
|
Infertility Global Clinical Trials Review, Q2, 2011 |
||
| 6 / 2011 | 773,40 € | |
|
Polycystic Ovarian Syndrome Global Clinical Trials Review, Q2, 2011 |
||
| 6 / 2011 | 773,40 € | |
|
Post Menopausal Osteoporosis Global Clinical Trials Review, Q2, 2011 |
||
Pregnancy Global Clinical Trials Review, Q2, 2011Von: GlobalData
|
6 / 2011 | 773,40 € |
|
Pregnancy Global Clinical Trials Review, Q2, 2011 |
||
Uterine Fibroids Global Clinical Trials Review, Q2, 2011Von: GlobalData
|
6 / 2011 | 773,40 € |
|
Uterine Fibroids Global Clinical Trials Review, Q2, 2011 |
||
Premenstrual Syndrome - Pipeline Review, Q2 2011Von: Global Markets Direct
|
5 / 2011 | 386,70 € |
|
Premenstrual Syndrome - Pipeline Review, Q2 2011 |
||
Post Menopausal Osteoporosis - Pipeline Review, Q2 2011Von: Global Markets Direct
|
4 / 2011 | 386,70 € |
|
Post Menopausal Osteoporosis - Pipeline Review, Q2 2011 |
||
Primary Dysmenorrhea - Pipeline Review, Q2 2011Von: Global Markets Direct
|
4 / 2011 | 386,70 € |
|
Primary Dysmenorrhea - Pipeline Review, Q2 2011 |
||
Dysmenorrhea - Pipeline Review, Q1 2011Von: Global Markets Direct
|
3 / 2011 | 386,70 € |
|
Dysmenorrhea - Pipeline Review, Q1 2011 |
||
Emergency Contraception - CanadaVon: Euromonitor
|
3 / 2011 | 675,00 € |
|
During 2010, retail sales of emergency contraception grew 13% to reach C$22 million in current value terms. Growth was slower compared to previous years of the review period, which saw significant sales growth as a result of greater access to the product (ie without prescription). Sales nonetheless remained strong throughout 2010 due to the declining teen pregnancy rate and growing preference for career over childbearing amongst Canadia... |
||
Female Sexual Dysfunction - Pipeline Review, Q1 2011Von: Global Markets Direct
|
3 / 2011 | 386,70 € |
|
Female Sexual Dysfunction - Pipeline Review, Q1 2011 |
||
Menopausal Disorders - Pipeline Review, Q1 2011Von: Global Markets Direct
|
3 / 2011 | 386,70 € |
|
Menopausal Disorders - Pipeline Review, Q1 2011 |
||
Menopausal Hot Flashes - Pipeline Review, Q1 2011Von: Global Markets Direct
|
3 / 2011 | 386,70 € |
|
Menopausal Hot Flashes - Pipeline Review, Q1 2011 |
||
Uterine Fibroids - Pipeline Review, Q1 2011Von: Global Markets Direct
|
3 / 2011 | 386,70 € |
|
Uterine Fibroids - Pipeline Review, Q1 2011 |
||
Vaginal Atrophy - Pipeline Review, Q1 2011Von: Global Markets Direct
|
3 / 2011 | 386,70 € |
|
Vaginal Atrophy - Pipeline Review, Q1 2011 |
||
Calming and Sleeping - USAVon: Euromonitor
|
2 / 2011 | 675,00 € |
|
In January 2010, Johnson & Johnson recalled nine lots of its leading brand Simply Sleep. The resulting lack of product availability and consumer scepticism devastated sales for the brand. Consumers responded by choosing private label alternatives, buying other brands and opting for alternative methods to help them sleep. Another possible option, selecting a night-time combination analgesic product, was also limited as Johnson & ... |
||
Emergency Contraception - ChinaVon: Euromonitor
|
2 / 2011 | 675,00 € |
|
The emergency contraception market in 2010 enjoyed 9% current value growth, higher than the 7% growth in 2009. Although a scandal concerning the side effects of levonorgestrel including extrauterine pregnancy, which involved Yuting, created some panic at the beginning of 2010, it did not affect the growth trend due to the growing demand for emergency contraception. |
||
Emergency Contraception - EstoniaVon: Euromonitor
|
2 / 2011 | 675,00 € |
|
Emergency contraception in Estonia stagnated as value sales record EEK7 million in 2010. However, the category survived the decline as the product is often considered a necessity. Women continued to purchase emergency contraception as unwanted pregnancy was a concept completely detached from the economic crisis. Women perceived these products to be essential to avoid pregnancy. Saving at the expense of this product was rather complicat... |
||
Emergency Contraception - LatviaVon: Euromonitor
|
2 / 2011 | 675,00 € |
|
Emergency contraception grew by less than 1% in 2010. This was due to the stability of prices in 2010. Volume growth of emergency contraception remained unchanged. |
||
Emergency Contraception - USAVon: Euromonitor
|
2 / 2011 | 675,00 € |
|
In August 2009, the FDA approved Watson Pharmaceuticals’ Next Choice emergency contraceptive for OTC sale. The drug is the generic bioequivalent of Plan B, and as Next Choice is priced 10-20% lower than Plan B, its sales took off as soon as it hit the market. In fact, by the end of 2010, sales of Next Choice in its first full year on the market surpassed those of Plan B to make Watson the new category leader. |
||
Endometriosis - Pipeline Review, Q1 2011Von: Global Markets Direct
|
2 / 2011 | 386,70 € |
|
Endometriosis - Pipeline Review, Q1 2011 |
||
Hormone Replacement Therapy - Pipeline Review, Q1 2011Von: Global Markets Direct
|
2 / 2011 | 386,70 € |
|
Hormone Replacement Therapy - Pipeline Review, Q1 2011 |
||
Infertility - Pipeline Review, Q1 2011Von: Global Markets Direct
|
2 / 2011 | 386,70 € |
|
Infertility - Pipeline Review, Q1 2011 |
||
Polycystic Ovarian Syndrome - Pipeline Review, Q1 2011Von: Global Markets Direct
|
2 / 2011 | 386,70 € |
|
Polycystic Ovarian Syndrome - Pipeline Review, Q1 2011 |
||
| 12 / 2010 | 2.706,88 € | |
|
Contraceptives Market to 2016 - Demand for Long Acting Birth Control Pills Encourages Growth in Hormonal Contraceptives Market |
||
Dysmenorrhea - Pipeline Assessment and Market Forecasts to 2017Von: GlobalData
|
12 / 2010 | 4.640,37 € |
|
Dysmenorrhea - Pipeline Assessment and Market Forecasts to 2017 |
||
Endometriosis - Pipeline Assessment and Market Forecasts to 2017Von: GlobalData
|
12 / 2010 | 1.546,79 € |
|
Endometriosis - Pipeline Assessment and Market Forecasts to 2017 |
||
| 12 / 2010 | 11.755,61 € | |
|
Introduction |
||
Urinary Incontinence Market ForecastVon: Datamonitor
|
12 / 2010 | 11.755,61 € |
|
Introduction |
||
| 8 / 2010 | 2.706,88 € | |
|
Women’s Health Therapeutics, Analysis and Market Forecasts to 2016 - High Unmet Need will Drive the Uptake of Novel Drugs in the Menopause and Osteoporosis Markets |
||
Emergency Contraception - BulgariaVon: Euromonitor
|
5 / 2010 | 675,00 € |
|
Emergency contraception sales in Bulgaria reached BGN1 million in 2009. This growth was driven by Escapelle, a product of the Hungarian company Richter Gedeon Ltd, launched in 2007. The launch was supported by a massive marketing campaign, which included television, radio, billboard and magazine advertisements and various sponsorships. This not only successfully popularised the product but also created consumer awareness of emergency c... |
||
Emergency Contraception - IranVon: Euromonitor
|
5 / 2010 | 337,00 € |
|
Emergency contraception recorded value sales of IRR410mn in 2009. It showed current value growth of 55% over the previous year, largely because the product is growing from a small base and retails at a high unit price. It showed good growth as a result of higher demand for this kind of product due to a change in cultural and sexual behaviour of Iranians, particularly the younger generation. |
||
Emergency Contraception - UkraineVon: Euromonitor
|
5 / 2010 | 675,00 € |
|
In 2009 in value terms the sales of emergency contraception increased by 39% to UAH11 million. Demand for this kind of medicine is not elastic. Moreover, the rising price of condoms (mainly imported) led to a rising number of unplanned pregnancies. Thus the demand for emergency contraception also had a positive rate of growth in 2009. |
||
Abnormal Uterine Bleeding Therapy Area Pipeline ReportVon: Life Science Analytics
|
4 / 2010 | 1.156,23 € |
|
Life Science Analytics', Abnormal Uterine Bleeding Therapy Area Pipeline Report contains detailed information on the abnormal uterine bleeding drug pipeline. This report provides insight into the pipeline status of abnormal uterine bleeding drugs by company and by stage as well as a summary of the latest news and developments in this area. |
||
Dysmenorrhea Therapy Area Pipeline ReportVon: Life Science Analytics
|
4 / 2010 | 1.156,23 € |
|
Life Science Analytics', Dysmenorrhea Therapy Area Pipeline Report contains detailed information on the dysmenorrhea drug pipeline. This report provides insight into the pipeline status of dysmenorrhea drugs by company and by stage as well as a summary of the latest news and developments in this area. |
||
Emergency Contraception - DenmarkVon: Euromonitor
|
4 / 2010 | 675,00 € |
|
In 2009, value sales of emergency contraception reached DKr11 million, up 3% in current terms on the previous year. Rising consumer awareness of the products’ existence and greater mistrust of the effectiveness of condoms are driving demand. Consumer trust is a key growth driver, and the longer emergency contraception stays successfully on the market, the more women will begin to trust such products and will use them when they think t... |
||
Emergency Contraception - FranceVon: Euromonitor
|
4 / 2010 | 675,00 € |
|
In 2009, sales of emergency contraception increased by 9% in current value terms, to reach EUR10mn. Demand for emergency contraception remained high, but the 2009 growth rate was lower than 2008. The extensive communication campaign undertaken by the French government and different organisations such as INPES (National Institute for Health Prevention and Education) increased public awareness of STDs (sexually transmitted diseases) and A... |
||
Emergency Contraception - SpainVon: Euromonitor
|
4 / 2010 | 675,00 € |
|
In 2009 the Spanish Government decided to allow sales of emergency contraception on an OTC basis. However, the fact the there are 17 different regions which are in charge of implementing this new law has resulted in Catañuña being the only region to actual sell these products OTC. Sales of emergency contraception products thus reached a value of just EUR0.8 million in 2009. |
||
Endometriosis Therapy Area Pipeline ReportVon: Life Science Analytics
|
4 / 2010 | 1.156,23 € |
|
Life Science Analytics', Endometriosis Therapy Area Pipeline Report contains detailed information on the endometriosis drug pipeline. This report provides insight into the pipeline status of endometriosis drugs by company and by stage as well as a summary of the latest news and developments in this area. |
||
Female Sexual Dysfunction Therapy Area Pipeline ReportVon: Life Science Analytics
|
4 / 2010 | 1.156,23 € |
|
Life Science Analytics', Female Sexual Dysfunction Therapy Area Pipeline Report contains detailed information on the female sexual dysfunction drug pipeline. This report provides insight into the pipeline status of female sexual dysfunction drugs by company and by stage as well as a summary of the latest news and developments in this area. |
||
Infertility Therapy Area Pipeline ReportVon: Life Science Analytics
|
4 / 2010 | 1.156,23 € |
|
Life Science Analytics', Infertility Therapy Area Pipeline Report contains detailed information on the infertility drug pipeline. This report provides insight into the pipeline status of infertility drugs by company and by stage as well as a summary of the latest news and developments in this area. |
||
Menopausal Symptoms Therapy Area Pipeline ReportVon: Life Science Analytics
|
4 / 2010 | 1.156,23 € |
|
Life Science Analytics', Menopausal Symptoms Therapy Area Pipeline Report contains detailed information on the menopausal symptoms drug pipeline. This report provides insight into the pipeline status of menopausal symptoms drugs by company and by stage as well as a summary of the latest news and developments in this area. |
||
| 4 / 2010 | 1.546,79 € | |
|
Polycystic Ovarian Syndrome - Drug Pipeline Analysis and Market Forecasts to 2016 |
||
Vaginal Infections Therapy Area Pipeline ReportVon: Life Science Analytics
|
4 / 2010 | 1.156,23 € |
|
Life Science Analytics', Vaginal Infections Therapy Area Pipeline Report contains detailed information on the Vaginal Infections drug pipeline. This report provides insight into the pipeline status of Vaginal Infections drugs by company and by stage as well as a summary of the latest news and developments in this area. |
||
| 3 / 2010 | 5.877,80 € | |
|
Introduction |
||
| 12 / 2009 | 8.816,71 € | |
|
Introduction |
||
| 9 / 2008 | 8.816,71 € | |
|
Introduction |
||
| 9 / 2008 | 8.816,71 € | |
|
Introduction |
||
| 6 / 2008 | 2.938,90 € | |
|
Introduction |
||
Kidneys and Genito-Urinary System Urinary IncontinenceVon: Life Science Analytics
|
4 / 2008 | 1.156,23 € |
|
Life Science Analytics', 'Kidneys and Genito-Urinary System Urinary Incontinence ' contains detailed information on the current drug pipeline. This report provides insight into the pipeline status of allergy drugs by company and by stage as well as a summary of the latest news and developments in this area. |
||
Metabolic Endocrinology HypogonadismVon: Life Science Analytics
|
4 / 2008 | 1.156,23 € |
|
Life Science Analytics', 'Metabolic Endocrinology Hypogonadism ' contains detailed information on the current drug pipeline. This report provides insight into the pipeline status of allergy drugs by company and by stage as well as a summary of the latest news and developments in this area. |
||
Women's Health ContraceptionVon: Life Science Analytics
|
4 / 2008 | 1.156,23 € |
|
Life Science Analytics', 'Women's Health Contraception ' contains detailed information on the current drug pipeline. This report provides insight into the pipeline status of allergy drugs by company and by stage as well as a summary of the latest news and developments in this area. |
||
Women's Health DysmenorrheaVon: Life Science Analytics
|
4 / 2008 | 1.156,23 € |
|
Life Science Analytics', 'Women's Health Dysmenorrhea ' contains detailed information on the current drug pipeline. This report provides insight into the pipeline status of allergy drugs by company and by stage as well as a summary of the latest news and developments in this area. |
||
Women's Health EndometriosisVon: Life Science Analytics
|
4 / 2008 | 1.156,23 € |
|
Life Science Analytics', 'Women's Health Endometriosis ' contains detailed information on the current drug pipeline. This report provides insight into the pipeline status of allergy drugs by company and by stage as well as a summary of the latest news and developments in this area. |
||
Women's Health Female Sexual DysfunctionVon: Life Science Analytics
|
4 / 2008 | 1.156,23 € |
|
Life Science Analytics', 'Women's Health Female Sexual Dysfunction ' contains detailed information on the current drug pipeline. This report provides insight into the pipeline status of allergy drugs by company and by stage as well as a summary of the latest news and developments in this area. |
||
Women's Health InfertilityVon: Life Science Analytics
|
4 / 2008 | 1.156,23 € |
|
Life Science Analytics', 'Women's Health Infertility ' contains detailed information on the current drug pipeline. This report provides insight into the pipeline status of allergy drugs by company and by stage as well as a summary of the latest news and developments in this area. |
||
Women's Health Labor and DeliveryVon: Life Science Analytics
|
4 / 2008 | 1.156,23 € |
|
Life Science Analytics', 'Women's Health Labor and Delivery ' contains detailed information on the current drug pipeline. This report provides insight into the pipeline status of allergy drugs by company and by stage as well as a summary of the latest news and developments in this area. |
||
Women's Health Menopausal SymptomsVon: Life Science Analytics
|
4 / 2008 | 1.156,23 € |
|
Life Science Analytics', 'Women's Health Menopausal Symptoms ' contains detailed information on the current drug pipeline. This report provides insight into the pipeline status of allergy drugs by company and by stage as well as a summary of the latest news and developments in this area. |
||
Women's Health Postmenopausal OsteoporosisVon: Life Science Analytics
|
4 / 2008 | 1.156,23 € |
|
Life Science Analytics', 'Women's Health Postmenopausal Osteoporosis ' contains detailed information on the current drug pipeline. This report provides insight into the pipeline status of allergy drugs by company and by stage as well as a summary of the latest news and developments in this area. |
||
Women's Health Vaginal InfectionsVon: Life Science Analytics
|
4 / 2008 | 1.156,23 € |
|
Life Science Analytics', 'Women's Health Vaginal Infections ' contains detailed information on the current drug pipeline. This report provides insight into the pipeline status of allergy drugs by company and by stage as well as a summary of the latest news and developments in this area. |
||
Jede Marktanalyse Frauenkrankheiten (Gynäkologie) wird sofort per eMail zur Verfügung gestellt und kann online oder per Fax bestellt werden. Falls Sie regelmäßig aktuelle Informationen, Daten und Analysen aus dem Bereich „Studie Frauenkrankheiten (Gynäkologie)“ erhalten möchten, nutzen Sie doch eines unserer zahlreichen Angebote, zum Beispiel unsere Research-Flatrate.
*Unser Angebot richtet sich an gewerbliche Kunden, daher sind alle Preise netto ausgewiesen.
In Abhngigkeit von Ihrer Rechnungsanschrift ist hierauf noch USt. zu entrichten (Deutschland z.Z. 19%).
Der korrekte Gesamtendpreis wird Ihnen nach Angabe Ihrer Rechnungsadresse im weiteren Bestellablauf ausgewiesen.


